Hyperion Therapeutics Announces Three New Additions to Its Senior Leadership Team

Hyperion Therapeutics Announces Three New Additions to Its Senior Leadership
Team

SOUTH SAN FRANCISCO, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics (Nasdaq:HPTX) announced today that the company has added three
new executives to its leadership team: senior vice president, governmental
affairs and chief legal officer, Ashley Gould, senior vice president,
Corporate and Business Development, Natalie Holles and vice president,
Investor Relations and Corporate Communications, Sylvia Wheeler.

"I am pleased with the varied breadth of related industry expertise each of
these individuals brings to our business," said Donald J. Santel, Chief
Executive Officer of Hyperion. "As we continue to mature as a company, their
respective experience and skills will be instrumental in helping to guide our
growth as a commercial enterprise seeking to deliver life-changing treatments
to the patient and medical communities we serve."

Senior Vice President, Governmental Affairs and Chief Legal Officer; Ashley
Gould

Ms. Gould will be responsible for serving as the company's in-house legal
counsel and leading public and governmental affairs activities. Ms. Gould
recently served as vice president, Corporate Development and chief legal
officer at 23andMe, a personal genetics company. Prior to joining 23andMe in
2007, Ms Gould was vice president, Legal Affairs at CoTherix, Inc., a
biopharmaceutical company. Previously, Ms. Gould was associated with the law
firms of Wilson Sonsini Goodrich & Rosati PC and O'Melveny & Myers LLP. Ms.
Gould received her JD from the University of San Francisco School of Law and
her B.S. in Political Economy of Natural Resources from the University of
California, Berkeley.

Senior Vice President, Corporate and Business Development; Natalie Holles

Ms. Holles will lead Hyperion's efforts to bring in new products to complement
the existing portfolio and identify other ways to grow the company through
external industry relationships. For the past five years, Ms. Holles has
worked as an executive-level consultant leading business development
activities for several life sciences companies. Most recently she served as
executive vice president of Corporate Development for Immune Design, a leading
cancer immunotherapy company based in Seattle. Ms. Holles also brings
extensive in-house business development experience from KAI Pharmaceuticals,
and InterMune, Inc. Ms. Holles began her career in theindustry as a Marketing
Planning Associate at Genentech, Inc. Ms. Holles received her M.A. in
Molecular, Cellular and Developmental Biology from the University of Colorado
and her A.B. in Human Biology from Stanford University.

Vice President, Investor Relations and Corporate Communications; Sylvia
Wheeler

Ms. Wheeler will lead Hyperion's strategic external communications initiatives
with the investment and media communities. Ms. Wheeler joins the team from
Affymax, Inc. a biopharmaceutical company where she most recently served as
vice president, Corporate Communications. Prior to joining Affymax in 2007,
Ms. Wheeler served as senior director, Corporate Communications for Depomed,
Inc., a specialty pharmaceutical company. Ms. Wheeler has also served in
similar functions at Cerus Corporation, a biomedical products company, Coulter
Pharmaceuticals, Inc. a biotechnology company and at Russell Welsh, a
communications agency focused exclusively on the bioscience industry. Ms.
Wheeler earned her M.B.A from the University of San Francisco and a B.A. in
Biology from San Francisco State University. 

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, Ravicti®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns and
markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide.For
more information, please visit www.hyperiontx.com.

CONTACT: Sylvia Wheeler, Investor Relations
         (650) 794-7834
 
Press spacebar to pause and continue. Press esc to stop.